New developments in immunotherapy for SCLC
Small cell lung cancer (SCLC) is an aggressive form of neuroendocrine neoplasm known for its striking initial response to treatment, followed by fast relapse and refractoriness in response to additional lines of therapy. New advances in immunotherapy are paving the way for more effective treatment s...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/1/e009667.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556612203937792 |
|---|---|
| author | Zhonglin Hao Tsering Dolkar Christopher Gates Reinhold Munker |
| author_facet | Zhonglin Hao Tsering Dolkar Christopher Gates Reinhold Munker |
| author_sort | Zhonglin Hao |
| collection | DOAJ |
| description | Small cell lung cancer (SCLC) is an aggressive form of neuroendocrine neoplasm known for its striking initial response to treatment, followed by fast relapse and refractoriness in response to additional lines of therapy. New advances in immunotherapy are paving the way for more effective treatment strategies and have promising results with early clinical trial data. While SCLC rarely harbors actionable mutations, the receptor DLL3 is extensively present in SCLC, making it a potential target for immunotherapy. Three emerging therapeutic options include bispecific T cell engagers targeting DLL3, chimeric antigen receptor T cells (CAR-T cells), and antibody–drug conjugates. Several phase II and phase III clinical trials for bispecific T cell engagers show promise. Additionally, the first CAR-T cell trials in humans for SCLC are currently underway. |
| format | Article |
| id | doaj-art-f0a71e3d4f9742b4b1de4084fabc9d90 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-f0a71e3d4f9742b4b1de4084fabc9d902025-01-07T07:55:12ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-01-0113110.1136/jitc-2024-009667New developments in immunotherapy for SCLCZhonglin Hao0Tsering Dolkar1Christopher Gates2Reinhold Munker3Medical Oncollogy, University of Kentucky, Lexington, Kentucky, USAHospital Medicine, University of Kentucky, Lexington, Kentucky, USAHematology - Oncology, University of Kentucky, Lexington, Kentucky, USAUniversity of Kentucky, Lexington, Kentucky, USASmall cell lung cancer (SCLC) is an aggressive form of neuroendocrine neoplasm known for its striking initial response to treatment, followed by fast relapse and refractoriness in response to additional lines of therapy. New advances in immunotherapy are paving the way for more effective treatment strategies and have promising results with early clinical trial data. While SCLC rarely harbors actionable mutations, the receptor DLL3 is extensively present in SCLC, making it a potential target for immunotherapy. Three emerging therapeutic options include bispecific T cell engagers targeting DLL3, chimeric antigen receptor T cells (CAR-T cells), and antibody–drug conjugates. Several phase II and phase III clinical trials for bispecific T cell engagers show promise. Additionally, the first CAR-T cell trials in humans for SCLC are currently underway.https://jitc.bmj.com/content/13/1/e009667.full |
| spellingShingle | Zhonglin Hao Tsering Dolkar Christopher Gates Reinhold Munker New developments in immunotherapy for SCLC Journal for ImmunoTherapy of Cancer |
| title | New developments in immunotherapy for SCLC |
| title_full | New developments in immunotherapy for SCLC |
| title_fullStr | New developments in immunotherapy for SCLC |
| title_full_unstemmed | New developments in immunotherapy for SCLC |
| title_short | New developments in immunotherapy for SCLC |
| title_sort | new developments in immunotherapy for sclc |
| url | https://jitc.bmj.com/content/13/1/e009667.full |
| work_keys_str_mv | AT zhonglinhao newdevelopmentsinimmunotherapyforsclc AT tseringdolkar newdevelopmentsinimmunotherapyforsclc AT christophergates newdevelopmentsinimmunotherapyforsclc AT reinholdmunker newdevelopmentsinimmunotherapyforsclc |